(Q88069689)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24924474%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

title

Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24924474%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

diffuse large B-cell lymphoma

1 reference

Guoqi Song

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24924474%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

William C Cho

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24924474%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Ling Gu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24924474%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Bangshun He

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24924474%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Yuqin Pan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24924474%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Shukui Wang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24924474%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

publication date

13 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24924474%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24924474%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24924474%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24924474%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24924474%20AND%20SRC:MED&resulttype=core&format=json

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

20 March 2020

cites work

1 reference

12 December 2020

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

1 reference

12 December 2020

Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis

1 reference

12 December 2020

Revised response criteria for malignant lymphoma

1 reference

12 December 2020

Mechanism of action and resistance to monoclonal antibody therapy

1 reference

12 December 2020

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

12 December 2020

rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia

1 reference

12 December 2020

Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era.

1 reference

12 December 2020

A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy

1 reference

12 December 2020

High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B-cell lymphoma

1 reference

12 December 2020

Validation of tissue microarray technology in breast carcinoma

1 reference

12 December 2020

Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.

1 reference

12 December 2020

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

12 December 2020

Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.

1 reference

12 December 2020

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells

1 reference

12 December 2020

Tissue microarrays for high-throughput molecular profiling of tumor specimens

1 reference

12 December 2020

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

12 December 2020

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma

1 reference

12 December 2020

New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice

1 reference

12 December 2020

Tissue microarrays for rapid linking of molecular changes to clinical endpoints

1 reference

12 December 2020

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

12 December 2020

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

12 December 2020

10.1007/S12032-014-0056-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24924474%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference